Zobrazeno 1 - 10
of 55
pro vyhledávání: '"J. Greg Slatter"'
Autor:
Diansong Zhou, Terry Podoll, Yan Xu, Ganesh Moorthy, Karthick Vishwanathan, Joseph Ware, J. Greg Slatter, Nidal Al‐Huniti
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 8, Iss 7, Pp 489-499 (2019)
Acalabrutinib, a selective, covalent Bruton tyrosine kinase inhibitor, is a CYP3A substrate and weak CYP3A/CYP2C8 inhibitor. A physiologically‐based pharmacokinetic (PBPK) model was developed for acalabrutinib and its active metabolite ACP‐5862 t
Externí odkaz:
https://doaj.org/article/3dd18b63fb5f4449a581ca63c1046d47
Autor:
Terry, Podoll, Paul G, Pearson, Allard, Kaptein, Jerry, Evarts, Gerjan, de Bruin, Maaike, Emmelot-van Hoek, Anouk, de Jong, Bart, van Lith, Hao, Sun, Stephen, Byard, Adrian, Fretland, Niels, Hoogenboom, Tjeerd, Barf, J Greg, Slatter
Publikováno v:
Journal of Pharmacology and Experimental Therapeutics. 384:173-186
Acalabrutinib is a covalent Bruton tyrosine kinase (BTK) inhibitor approved for relapsed/refractory mantle cell lymphoma and chronic lymphocytic leukemia/small lymphocytic lymphoma. A major metabolite of acalabrutinib (M27, ACP-5862) was observed in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e5b51ca94d968a8dbd551ff1f2f6f4a3
https://doi.org/10.1124/jpet.122.001116
https://doi.org/10.1124/jpet.122.001116
Autor:
Shekman, Wong, Cecile, Krejsa, Dana, Lee, Anna, Harris, Emilie, Simard, Xiaohui, Wang, Martine, Allard, Terry, Podoll, Terry, O'Reilly, J Greg, Slatter
Publikováno v:
Clinical Pharmacology in Drug Development. 11:640-653
This single 60-mg dose, 4-period crossover study assessed the effect of food and formulation change on navtemadlin (KRT-232) pharmacokinetics (PK) and macrophage inhibitory cytokine-1 (MIC-1) pharmacodynamics. Healthy subjects (N = 30) were randomize
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5fb2442e7f2a7b8eeb80df2aa9cffbd8
https://doi.org/10.1002/cpdd.1070
https://doi.org/10.1002/cpdd.1070
Autor:
Yan Xu, Raquel Izumi, Helen Nguyen, Anna Kwan, Howard Kuo, Jeannine Madere, J. Greg Slatter, Terry Podoll, Karthick Vishwanathan, Thomas Marbury, William Smith, Richard A. Preston, Shringi Sharma, Joseph A. Ware
Publikováno v:
The Journal of Clinical Pharmacology. 62:812-822
Acalabrutinib received approval for the treatment of adult patients with mantle cell lymphoma who received at least 1 prior therapy and adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma. This study investigated the impact
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::483cdfccd5e3d0afc099ab532cad2d9b
https://doi.org/10.1002/jcph.2013
https://doi.org/10.1002/jcph.2013
Publikováno v:
Clinical Pharmacology in Drug Development
Cardiac safety and plasma concentration‐QTc interval analyses were completed using data from 2 phase 1 studies of the selective mouse double minute chromosome 2 antagonist, KRT‐232, in patients with solid tumors or multiple myeloma and acute myel
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::96ea6ccb6c4f5a265f0edf9929a4ef82
https://doi.org/10.1002/cpdd.903
https://doi.org/10.1002/cpdd.903
Navtemadlin is a potent, selective, orally available inhibitor of murine double minute 2 that restores p53 activity to induce apoptosis in TP53 wild-type malignancies. Using richly sampled pharmacokinetic (PK) and pharmacodynamic (PD) data from healt
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3364555f0c97e4a11303bac4daaba2a5
Autor:
Mark Gohdes, J. Greg Slatter, Tim Ingallinera, Hao Sun, Paul G. Pearson, Jerry Evarts, Terry Podoll, Mitesh Sanghvi, Elena Bibikova, Kristen Cardinal
Publikováno v:
Drug Metabolism and Disposition. 47:145-154
Acalabrutinib is a targeted, covalent inhibitor of Bruton tyrosine kinase (BTK) with a unique 2-butynamide warhead that has relatively lower reactivity than other marketed acrylamide covalent inhibitors. A human [14C] microtracer bioavailability stud
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ecdd79c4d40f1d5137e0bc6c0ef781ad
https://doi.org/10.1124/dmd.118.084459
https://doi.org/10.1124/dmd.118.084459
Publikováno v:
Blood. 138:4350-4350
Background: Murine double minute 2 (MDM2) is the primary negative regulator of the tumor suppressor protein, p53. Navtemadlin (KRT-232), a potent and selective, orally available MDM2 inhibitor restores p53 activity to drive apoptosis of cancer cells
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4bffedad52126598f8c4228282923abb
https://doi.org/10.1182/blood-2021-145205
https://doi.org/10.1182/blood-2021-145205
Publikováno v:
Blood. 136:9-10
Background: KRT-232 is a potent, selective, orally available, targeted inhibitor of human MDM2 homolog interactions with tumor suppressor protein 53 (p53). KRT-232 is under development for treatment of myeloproliferative neoplasms, acute myeloid leuk
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a06670ee8964546d9fd836682a2e1315
https://doi.org/10.1182/blood-2020-135987
https://doi.org/10.1182/blood-2020-135987
Autor:
Anna L. Harris, J. Greg Slatter, Xiaohui Wang, Dana Lee, Terry Podoll, Cecile M. Krejsa, Martine Allard, Terry O'Reilly, Shekman Wong, Emilie Simard, Igor Rubets
Publikováno v:
Blood. 136:7-8
Background: KRT-232 is a potent, selective, orally available, small-molecule drug that binds to mouse double minute 2 homolog (MDM2) and inhibits its interactions with tumor suppressor protein p53. KRT-232 is under development for treatment of myelop
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cf0e71cae8c40ac85159ae36d4144889
https://doi.org/10.1182/blood-2020-135985
https://doi.org/10.1182/blood-2020-135985